Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE)

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

February 16, 2016

Primary Completion Date

September 5, 2019

Study Completion Date

July 11, 2020

Conditions
NonHodgkin LymphomaLymphoproliferative DisordersEBV Related LymphomaEBV-Related PTLDHodgkin LymphomaEBV Related Non-Hodgkin's LymphomaEBV Related Hodgkin's Lymphoma
Interventions
BIOLOGICAL

EBVST Cells

EBVST cells in an expected volume of 10-20cc will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.

BIOLOGICAL

Nivolumab

Nivolumab 3mg/kg (max dose: 240 mg) will be administered as an intravenous infusion over 60 minutes.

Trial Locations (2)

77030

Houston Methodist Hospital, Houston

Texas Children's Hospital, Houston

All Listed Sponsors
collaborator

The Methodist Hospital Research Institute

OTHER

collaborator

Center for Cell and Gene Therapy, Baylor College of Medicine

OTHER

lead

Baylor College of Medicine

OTHER

NCT02973113 - Nivolumab With Epstein Barr Virus Specific T Cells (EBVSTS), Relapsed/Refractory EBV Positive Lymphoma (PREVALE) | Biotech Hunter | Biotech Hunter